

가

Two Cases with Carbamazepine-induced Unusual Side Effects -Encephalopathy and Myoclonic Jerks-

Seon-Young Ryu, M.D., Ji-Yeon Lee, M.D., Kyu-Hwan Lee, M.D.,
Seong-Min Park, M.D., Si-Ryung Han, M.D., Yeong-In Kim, M.D.

Department of Neurology, College of Medicine, The Catholic University of Korea

Central nervous system toxicity is the most commonly recognized problem during treatment with carbamazepine (CBZ). The most common side effects of CBZ are drowsiness, incoordination, and vertigo. However, unusual conditions such as movement disorders, seizure aggravation, and encephalopathy have also been attributed to CBZ therapy. In case 1, cognitive dysfunction and exacerbation of preexisting gait disturbance were observed in a 63-year-old female who had frontal lobe epilepsy, schizencephaly, and lissencephaly treated with CBZ. The neurological symptoms were resolved 24 hours after the withdrawal of CBZ and induced with the reintroduction of CBZ. In case 2, myoclonic jerks occurred in a 37-year-old female when CBZ was readministered after a 4-day-withdrawal period of CBZ. The myoclonic jerks disappeared 12 days after CBZ was discontinued. In both cases, plasma CBZ levels were within the therapeutic range. We report two cases with encephalopathy and myoclonic jerks as unusual side effects of CBZ, with the plasma levels of CBZ being within the therapeutic range.

J Korean Neurol Assoc 18(2):229~231, 2000

Key Words : Carbamazepine, Encephalopathy, Myoclonic jerks, Side effects

Carbamazepine(CBZ)

가 1
63 가 1
(asterixis),
CBZ 가
가
CBZ CBZ 1000 mg
1-3 CBZ
(myoclonic jerk)
grade IV+ 가

가 (dystonia)
(lissencephaly),
(schizencephaly), (septum pellu-
cidum)

Manuscript received August 10, 1999.
Accepted in final form December 10, 1999.

* Address for correspondence

Seon-Young Ryu, M.D.
Department of Neurology, College of Medicine,
The Catholic University of Korea
Banpo-dong 505, Seocho-ku, Seoul, 137-040, Korea
Tel : +82-2-590-2091,2092 Fax : +82-2-599-9686
E-mail : streamlined@hanmail.net

11 CBZ CBZ-E
 10 Gillhan
 CBZ
 CBZ-E CBZ-E가
 phenytoin phenobarbital
 epoxidation VPA CBZ-E
 1 CBZ
 CBZ 24
 CBZ 2 4 CBZ
 4
 12 CBZ
 , CBZ-E
 CBZ
 가
 , CBZ
 CBZ-E 가 , CBZ
 CBZ CBZ-E

REFERENCES

1. Pellock JM. Carbamazepine side effects in children and adults. *Epilepsia* 1987;28(Suppl.3):S64-S70.
2. Smith CR. Encephalomyelopathy as an idiosyncratic reaction to carbamazepine: a case report. *Neurology* 1991; 41:760-761.

3. Salcman M, Pippenger CE. Letter: Acute carbamazepine encephalopathy. *JAMA* 1975;231(9):915.
4. Bimoibg-Buta K, Froescher W. Carbamazepine-induced choreoathetoid dyskinesias. *J Neuro Neurosurg Psychiatry* 1998 ;45(6):560.
5. Aguglia U, Zapia M, Quattrone A. Carbamazepine-induced non-epileptic myoclonus in a child with benign epilepsy. *Epilepsia* 1987;28:515-518.
6. Dhuna A, Pascual-Leone A, Talwar D. Exacerbation of partial seizures and onset of nonepileptic myoclonus with carbamazepine. *Epilepsia* 1991;32(2):275-278.
7. Schoeman JF, Elyas AA, Brett EM, Lascelles PT. Correlation between plasma carbamazepine-10,11-epoxide concentration and drug side-effects in children with epilepsy. *Dev Med Child Neurol* 1984;26:756-764.
8. Riva R, Contin M, Albani F, Perucca E, Ambrosetto G, Gobbi G, et al. Free and total plasma concentrations of carbamazepine and carbamazepine-10,11-epoxide in epileptic patients: diurnal fluctuations and relationship with side effects. *Ther Drug Monit* 1984;6:408-413.
9. Rambeck B, May T, Juerens U. Serum concentrations of carbamazepine and its epoxide and diol metabolites in epileptic patients: the influence of dose and comedication. *Ther Drug Monit* 1987;9(3):298-303.
10. Nardzay JFX, Olshaker JS. Antiepileptic drug therapy: clinical laboratory significance. *The Journal of Emergency Medicine* 1996;14(4):473-481.
11. Gillham RA, Williams N, Wiedmann K, Butler E, Larkin JG, Brodie MF, et al. Concentration-effect relationships with carbamazepine and its epoxide on psychomotor and cognitive function in epileptic patients. *J Neuro Neurosurg Psychiatry* 1988;51:929-933.